p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors

Neoplasia

Volumn 10, Issue 11, 2008, Pages 1231-1239

  Gallagher, Stuart J ^a   Thompson, John F ^b   Indsto, James ^a   Scurr, Lyndee L ^a   Lett, Margaret ^b   Gao, Bo Fu ^a   Dunleavey, Ruth ^a   Mann, Graham J ^a,b   Kefford, Richard F ^a,b   Rizos, Helen ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DACTINOMYCIN; MELPHALAN; MESSENGER RNA; MITFM PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITF PROTEIN, HUMAN; PTEN PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL DEATH; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INFUSION SYSTEM; MALE; MELANOMA; METASTASIS; MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; APOPTOSIS; CELL CYCLE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; ONCOGENE RAS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DACTINOMYCIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; GENES, RAS; HUMANS; MALE; MELANOMA; MELPHALAN; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 55849122635     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08702     Document Type: Article

References (60)

1. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, et al. (2001). Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19, 3622-3634.
2. Eggermont AM and Kirkwood JM (2004). Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 40, 1825-1836.
3. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, et al. (2000). Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18, 158-166.
4. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, et al. (2004). Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22, 1118-1125.
5. Coates AS and Segelov E (1994). Long term response to chemotherapy in patients with visceral metastatic melanoma. Ann Oncol 5, 249-251.
6. Thompson JF, Kam PC, Waugh RC, and Harman CR (1998). Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 14, 238-247.
7. Thompson JF, Scolyer RA, and Kefford RF (2005). Cutaneous melanoma. Lancet 365, 687-701.
8. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, et al. (2005). Distinct sets of genetic alterations in melanoma. N Engl J Med 353, 2135-2147.
9. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, et al. (2006). Features associated with germline CDKN2A mutations: a GenoMEL study of melanomaprone families from three continents. J Med Genet 44, 99-106.
10. ARF induces p53-dependent cell cycle arrest but not apoptosis. Cell Cycle 4, 465-472.
11. ARF in radio- and chemosensitivity of malignant gliomas. Oncol Rep 16, 127-132.
12. Williams RT, Roussel MF, and Sherr CJ (2006). Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci USA 103, 6688-6693.
13. ARF sensitizes human osteosarcoma cells to cisplatin-induced apoptosis in a p53-independent manner. Cancer Biol Ther 6, 7.
14. Sherr CJ (2006). Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6, 663-673.
15. Serrano M, Hannon GJ, and Beach D (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704-707.
16. 1 arrest by p16 (INK4A) uncouples growth from cell cycle progression in leukemia cells with deregulated cyclin E and c-Myc expression. Leukemia 19, 1051-1057.
17. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Kuo C, Wang HJ, Milford R, Morton DL, et al. (2006). Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res 12, 1137-1143.
18. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, Lin YL, Ramaswamy S, Avery W, Ding HF, et al. (2002). Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109, 707-718.
19. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122.
20. Loercher AE, Tank EMH, Delston RB, and Harbour JW (2005). MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 168, 35-40.
21. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, et al. (2003). High frequency of BRAF mutations in nevi. Nat Genet 33, 19-20.
22. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
23. Houben R, Becker JC, Kappel A, Terheyden P, Brocker EB, Goetz R, and Rapp UR (2004). Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3, 6.
24. Hocker T and Tsao H (2007). Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 28, 578-588.
25. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, and Hansson J (2002). Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 8, 3468-3474.
26. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S, and Hemminki K (2003). BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 9, 3362-3368.
27. Tsao H, Goel V, Wu H, Yang G, and Haluska FG (2004). Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122, 337-341.
28. Zhang W, Tsan R, Nam DH, Lu W, and Fidler IJ (2006). Loss of adhesion in the circulation converts amelanotic metastatic melanoma cells to melanotic by inhibition of AKT. Neoplasia 8, 543-550.
29. Liu J and Kagan J (1999). Method to distinguish between the MMAC1/PTEN gene and its pseudogene in RT-PCR analysis of point mutations. Biotechniques 26, 19-24.
30. INK4a mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding. Clin Cancer Res 7, 3282-3288.
31. Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, Redman B, Thomas NE, and Gruber SB (2006). BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16, 267-273.
32. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, and Meyerson M (2002). Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 62, 7001-7003.
33. Akslen LA, Puntervoll H, Bachmann IM, Straume O, Vuhahula E, Kumar R, and Molven A (2008). Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 18, 29-35.
34. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, et al. (2006). Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38, 294-296.
35. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, and Rauen KA (2006). Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311, 1287-1290.
36. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867.
37. Garnett MJ, Rana S, Paterson H, Barford D, and Marais R (2005). Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 20, 963-969.
38. Ugurel S, Thirumaran RK, Bloethner S, Gast A, Sucker A, Mueller-Berghaus J, Rittgen W, Hemminki K, Becker JC, Kumar R, et al. (2007). B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS ONE 2, e236.
39. Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR, Pointer JN, Gruber SB, Su LD, Nikiforov MA, et al. (2006). Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 8, 1053-1063.
40. Xu C, Bailly-Maitre B, and Reed JC (2005). Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 115, 2656-2664.
41. Chen LH, Jiang CC, Kiejda KA, Wang YF, Thorne R, Zhang XD, and Hersey P (2007). Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response. Carcinogenesis 28, 2328-2336.
42. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, and Khavari PA (2005). Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 37, 745-749.
43. Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, Walker GJ, Boyle GM, Harper U, Cozzi SJ, et al. (2004). Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23, 4060-4067.
44. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362.
45. Tsao H, Zhang X, Fowlkes K, and Haluska FG (2000). Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 60, 1800-1804.
46. Zhou XP, Li YJ, Hoang-Xuan K, Laurent-Puig P, Mokhtari K, Longy M, Sanson M, Delattre JY, Thomas G, and Hamelin R (1999). Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 84, 150-154.
47. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, and Eng C (2000). Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92, 924-930.
48. Meier F, Busch S, Lasithiotakis K, Kulms D, Garbe C, Maczey E, Herlyn M, and Schittek B (2007). Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 156, 1204-1213.
49. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, Nishimura EK, Golub TR, and Fisher DE (2004). Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6, 565-576.
50. Rambow F, Piton G, Bouet S, Leplat JJ, Baulande S, Marrau A, Stam M, Horak V, and Vincent-Naulleau S (2008). Gene expression signature for spontaneous cancer regression in melanoma pigs. Neoplasia 10, 714-726; 711 p following 726.
51. Wellbrock C and Marais R (2005). Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol 170, 703-708.
52. McGill GG, Haq R, Nishimura EK, and Fisher DE (2006). c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem 281, 10365-10373.
53. ARF tumor suppressor predicts survival in acute myeloid leukemia. Leukemia 18, 720-726.
54. ARF protein expression is a predictor of both relapse and survival in squamous cell carcinoma of the anterior tongue. Clin Cancer Res 11, 4107-4116.
55. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, et al. (2006). Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98, 472-482.
56. Sherr CJ (2001). The INK4a/ARF network in tumour suppression. Nat Rev 2, 731-737.
57. Mihic-Probst D, Mnich CD, Oberholzer PA, Seifert B, Sasse B, Moch H, and Dummer R (2006). p16 expression in primary malignant melanoma is associated with prognosis and lymph node status. Int J Cancer 118, 2262-2268.
58. Ota N, Kawakami K, Okuda T, Takehara A, Hiranuma C, Oyama K, Ota Y, Oda M, and Watanabe G (2006). Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis. Anticancer Res 26, 3729-3732.
59. INK4a and p16β transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations. Oncogene 15, 515-523.
60. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, and Kamb A (1995). Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55, 2988-2994.